Clinical trials: Splenomegaly
Hepato-splenomegaly, Dysostosis Multiplex
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)
Development of a new MS-based biomarker for the ear-ly and sensitive diagnosis of GM1/GM2 from blood
- Conditions
- Hepato-splenomegaly, Dysostosis Multiplex, Seizures, Mental Retardation
- Trial name
- BioGM1/BioGM2 (NCT02298647)
- Where
- 5 sites in Egypt, Germany and 2 more
- Sponsor
- CENTOGENE GmbH Rostock
Developmental Delay, Skeletal Abnormalities
Biomarker for Sly Disease (MPS VII) (BioSly)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Sly disease from blood (plasma)
- Conditions
- Developmental Delay, Skeletal Abnormalities, Hepatomegaly, Splenomegaly
- Trial name
- BioSly (NCT02298699)
- Where
- 5 sites in Egypt, Germany and 2 more
- Sponsor
- CENTOGENE GmbH Rostock
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
MPN-RC 118 AVID200 in Myelofibrosis
Increased levels of TGF-β1 were detected in serum, plasma and BM and positively correlated with both grade of BMF and extent of leukemic cell infiltration in the marrow.
- Conditions
- Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post ET MF
- Trial name
- NCT03895112
- Testing
- AVID200
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- John Mascarenhas
Gaucher Disease, Splenomegaly
A National Study in Patients With Unexplained Splenomegaly
Primary Objective: To estimate the prevalence of Gaucher disease and of other etiologies, in patients of 15 years old or more presenting with unexplained splenomegaly after exclusion of first intention-diagnoses (e.g.
- Trial name
- SMS (NCT04430881)
- Where
- France
- Volunteers
- 506 people
- Sponsor
- Sanofi
Splenomegaly; Congestive, Chronic, Panhematopenia; Splenic
Ultrasound Guided Microwave Ablation of Splenomegaly in Children
Children with liver cirrhosis frequently develops portal hypertension. One of the serious complications to portal hypertension is splenomegaly, which may result in pancytopenia, especially thrombocytopenia that may cause bleeding…
- Conditions
- Splenomegaly; Congestive, Chronic, Panhematopenia; Splenic, Portal Hypertension
- Trial name
- NCT05050994
- Testing
- Microwave ablation
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- Karolinska Institutet
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with thrombocytopenia and primary or secondary myelofibrosis.
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- PAC326 (NCT02055781)
- Testing
- Pacritinib, Best Available Therapy
- Where
- 122 sites in United States, Australia and 10 more
- Volunteers
- 311 people
- Sponsor
- CTI BioPharma
Cholecystitis, Perforated Duodenal Ulcer
Incentive Spirometry and Upper Abdominal Laparoscopic Surgery
To compare the effects of volume-oriented versus flow-oriented incentive spirometry on pulmonary function tests and functional capacity in patients of upper abdominal laparoscopic surgery.
- Conditions
- Cholecystitis, Perforated Duodenal Ulcer, Diaphragmatic Hernia, Benign Pancreas Tumor
- Trial name
- NCT04716166
- Testing
- Volume-oriented incentive spirometry, Flow-oriented incentive spirometry
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Riphah International University
Infectious Mononucleosis, Splenomegaly
The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department
The purpose of this study is to determine if splenomegaly on point-of-care ultrasound (POCUS) is an accurate and user-friendly surrogate to the heterophile antibody test and Epstein-Barr Virus (EBV) serologies to diagnose acute…
- Trial name
- NCT02463669
- Testing
- Point-of-care ultrasound
- Where
- 2 sites in Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Jewish General Hospital
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with primary or secondary myelofibrosis.
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01773187
- Testing
- Pacritinib, Best Available Therapy
- Where
- 81 sites in United States, Australia and 10 more
- Volunteers
- 327 people
- Sponsor
- CTI BioPharma
Gastroesophageal Varices, Colorectal Cancer
Early Diagnosis of Oxaliplatin-induced Portal Hypertension
Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer.
- Conditions
- Gastroesophageal Varices, Colorectal Cancer, Received Oxaliplatin-based Chemotherapy
- Trial name
- NCT04524650
- Testing
- the level of vWF
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Shanghai Zhongshan Hospital
Gastroesophageal Varices Hemorrhage, Colorectal Cancer
Oxaliplatin-induced Portal Hypertension
Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer.
- Conditions
- Gastroesophageal Varices Hemorrhage, Colorectal Cancer, Received Oxaliplatin-based Chemotherapy
- Trial name
- NCT04524676
- Testing
- Individualized Treatment
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Zhongshan Hospital
Leukemia, Myelofibrosis
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
The goal of this clinical research study is to learn if rigosertib can help to control MF in patients with anemia. The safety of this drug will also be studied. This is an investigational study.
- Conditions
- Leukemia, Myelofibrosis, Anemia, Splenomegaly
- Trial name
- NCT02730884
- Testing
- Rigosertib, Questionnaire
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia
Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
This phase II trial studies how well nivolumab works in treating patients with primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.
- Conditions
- Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
- Trial name
- NCT02421354
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Gaucher Disease
Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
This is an open-label expanded access trial of prGCD in patients with Gaucher disease who require enzyme replacement therapy (ERT) and who have been treated with imiglucerase but for whom the dose has been reduced or discontinued…
- Trial name
- NCT00962260
- Testing
- Plant cell expressed recombinant glucocerebrosidase (prGCD)
- Where
- 15 sites in United States, Israel
- Sponsor
- Pfizer
Thalassemia Major
Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
Patients with severe thalassemia (thalassemia major) present with severe anemia that required life-long transfusion therapy, spleen enlargement that led to increased transfusion requirement, and other serious complications as…
- Trial name
- NCT02049450
- Testing
- ruxolitinib
- Where
- 7 sites in Greece, Italy and 3 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Splenomegaly
Ultrasound Estimation of Spleen Size
In internal medicine, assessment of spleen size on physical examination is an extremely important part of the overall evaluation of patients with many illnesses.
- Trial name
- NCT01810419
- Testing
- Vscan Ultrasound (GE Healthcare, USA), Conventional Ultrasound
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- University of British Columbia
Splenomegaly
Estimation of Spleen by Residents With VScan
In internal medicine, assessment of spleen size on physical examination is an extremely important part of the overall evaluation of patients with many illnesses.
- Trial name
- NCT01907932
- Testing
- VScan Ultrasound (GE Healthcare, USA)
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- University of British Columbia
Hyper-reactive Malarial Splenomegaly, Malaria
Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly
This randomized clinical trial will address a complication related to recurrent episodes of malaria in endemic areas - hyper-reactive malarial splenomegaly.
- Conditions
- Hyper-reactive Malarial Splenomegaly, Malaria, Anaemia
- Trial name
- LiHMS (NCT01785979)
- Testing
- prednisone induction - chloroquine, Chloroquine
- Where
- Papua New Guinea
- Sponsor
- Lihir Medical Centre
Splenomegaly, Pleural Effusion
Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination
The 40 resident study subjects will be randomized to either receive a training session on use of a pocket-sized ultrasound or to receive training on physical exam skills.
- Trial name
- NCT01948076
- Testing
- resident with GE vscan
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
ALPS, Hypersplenism
Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)
This study will test whether valproic acid (Depakote[Registered Trademark]) can shrink enlarged lymph glands and spleen in patients with autoimmune lymphoproliferative syndrome (ALPS).
- Conditions
- ALPS, Hypersplenism, Lymphadenopathy
- Trial name
- NCT00605657
- Testing
- Valproic Acid, CT Scan, Blood Sample
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Koneti Rao